Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Tuesday, 2 July 2019

Investorideas.com - Cannex (CSE: CNNX; OTCQX: CNXXF) secures licensing and infrastructure to support major strategic California expansion

Investorideas.com - Cannex (CSE: CNNX; OTCQX: CNXXF) secures licensing and infrastructure to support major strategic California expansion

Investorideas.com - Cannabis Stock News: KushCo Holdings (OTCQX:$KSHB) Partners with C.A. Fortune to Expand Retail Opportunities for CBD Brands

Investorideas.com - Cannabis Stock News: KushCo Holdings (OTCQX:$KSHB) Partners with C.A. Fortune to Expand Retail Opportunities for CBD Brands

Investorideas.com - Indus Holdings, Inc. (CSE:INDS) Honored At Monterey County Business Council Economic Vitality Awards Gala

Investorideas.com - Indus Holdings, Inc. (CSE:INDS) Honored At Monterey County Business Council Economic Vitality Awards Gala

Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move (TSXV: $KHRN.V) (OTCQB: $KHRNF), (CSE: $MYM.C) (OTCBB: $MYMMF) (NASDAQ: $OGI)


Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move (TSXV: $KHRN.V) (OTCQB: $KHRNF), (CSE: $MYM.C) (OTCBB: $MYMMF) (NASDAQ: $OGI)

Also featured in today’s potcast- (CSE: $HUGE.C) (OTCQB: $FSDDF) (TSXV: $OGI.V), (TSX: $IN.TO) (OTCQX: $IMLFF)



Delta, Kelowna, BC –July 2, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:



Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today we are looking at a few early announcements.

But first, Health Minister Simon Harris signed legislation which will now allow Irish citizens access to cannabis-based products for medical use on a pilot basis for five years. The new Medical Cannabis Access Programme  allows medical consultants to prescribe medicinal cannabis of a standardised quality to patients who have failed to respond to standard treatments.

Minister Harris first proposed the programme two years ago, but its passage through the Dáil was delayed amid problems finding a quality-assured supplier of medicinal cannabis able to export its products to Ireland.
Earlier this year, it was confirmed that a supplier had been identified and the legislation was finally signed this morning.
The new scheme will facilitate access to medical cannabis for patients with the following conditions if they have failed to respond to standard treatments:
      Spasticity associated with multiple sclerosis
      Intractable nausea and vomiting associated with chemotherapy
      Severe, refractory (treatment-resistant) epilepsy
Commenting on the launch today, Mr Harris said: "It is important to state that there are no plans to legalise cannabis in this country.
"The purpose of this programme is to facilitate compassionate access to cannabis for medical reasons, where conventional treatment has failed.
"Ultimately it will be the decision of the medical consultant, in consultation with their patient, to prescribe a particular treatment, including a cannabis-based treatment, for a patient under their care."
Previously, there were no medical cannabis products available in Ireland and many sufferers were forced to spend thousands each year to access cannabis-based treatments in countries such as the Netherlands.
The new legislation means that commercial operators whose cannabis products meet the specified requirements will be able to supply products to the Irish market.
The Medical Cannabis Access Programme will operate on a pilot basis for five years before a review in 2024.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF), commented on the EU-Mercosur Trade Agreement announced between the European Union and Mercosur, the Latin American trading block made up of Argentina, Brazil, Uruguay and Paraguay. Khiron is active among Mercosur jurisdictions with a recently completed acquisition of NettaGrowth International, a cannabis company based in Uruguay.

The trade deal between the European Union and Mercosur announced on June 28, 2019 at the G20 Summit in Japan, which is subject to ratification by member countries, establishes a trade framework for goods and services, including pharma and medical products, covering nearly 780 million consumers, making it the largest in the world in terms of population, and with an estimated trade in goods of 88 Billion Euros (Source: European Commission).

Alvaro Torres, Khiron CEO and Director, comments "As we build Khiron's dominant position in Latin America and Mercosur markets through our operations in Uruguay, we welcome this trade deal as it strengthens our ability to now directly supply the European medical cannabis market. This significant milestone is another step towards a globalized medical cannabis trade network where Latin America, with its strategic location, many natural advantages and regulatory leadership, will continue to play a significant part."

Khiron announced completion of the acquisition of NettaGrowth International on June 19, 2019. NettaGrowth, and its wholly-owned subsidiary Dormul S.A. is a Uruguayan company that has obtained one of the first licences to produce and export medical cannabis with THC for commercialization in Uruguay, and is positioned to serve Brazil and the growing Latin American market as part of the Mercosur trading block, adopting the Company's scalable model as markets develop.

MYM Nutraceuticals Inc. (CSE: MYM) (OTCBB: MYMMF) announced that its subsidiary in Colombia, Colombia Organica S.A.S, has signed agreements in principle to cultivate both THC and CBD-rich cannabis with independent farmers for an initial five acres.

Cannabis will be cultivated by farmers who will be licensees under the existing Colombia Organica cannabis cultivation licenses. The first crops cultivated on the initial five acres will function as test crops with the intention to add subsequent acreage. The climate in Colombia is ideal for cultivating cannabis, with the growing season being year-round it's possible to harvest three crops of THC or CBD-rich cannabis annually.

"Our team in Colombia has begun to execute on our plan to cultivate both THC and CBD-rich cannabis in South America," said Howard Steinberg, CEO of MYM. "The strategy of extending our licenses to neighbouring farmers to cultivate cannabis will serve to increase our biomass supply that we intend on processing and exporting to the global market."

Colombia Organica is committed to extending its licenses to the independent farmers for an initial period of five years. The farmers will be responsible for all costs associated with cultivation from seed to sale. Colombia Organica agrees to purchase the harvested biomass at a price to be determined at the time of delivery based on the average market price at that time.

MYM is currently finalizing the closing documents that will see its own 80% of Colombia Organica.

Organigram Holdings Inc. (NASDAQ: OGI) (TSXV: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, announced today it will report its third quarter earnings results for its fiscal year ended August 31, 2019 on Monday, July 15, 2019 before market open. 

The Company will host a conference call to discuss its third quarter 2019 earnings results at 8am EST.

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.


FSD Pharma Inc. (CSE:HUGE) (OTCQB: FSDDF) and Prismic Pharmaceuticals Inc., a U.S.-based specialty R&D pharmaceutical company, have announced that, on June 28, 2019, they finalized the acquisition by FSD Pharma of all of the issued and outstanding securities of Prismic for an aggregate purchase price of approximately US$17.5 million, satisfied by the issuance of approximately 102.7 million Class B subordinate voting shares in the capital of FSD Pharma at a deemed price of CAD$0.2275 per FSD Share. In addition, FSD Pharma has agreed to assume approximately US$3.05 million of outstanding Prismic long- and short-term liabilities.

FSD Pharma will continue to be led by Raza Bokhari, MD, executive co-chairman and CEO. Zachary Dutton, co-founder of Prismic, will continue to serve as the CEO of Prismic, reporting to Edward Brennan, Jr. MD, FACS, president of the FSD Biosciences Division.

Peter Moriarty, co-founder and previous chairman of the board of Prismic, has been named chairman of the newly-formed FSD BioPharmaceutical Industry Advisory Board.

Bokhari stated, “On behalf of the FSD Pharma shareholders and Board of Directors, it is with immense pleasure that I welcome Prismic shareholders and stakeholders to the FSD Pharma family. Over the past several weeks, Dr. Brennan and our M&A team have worked very closely with the Prismic leadership to finalize this transaction under budget and ahead of schedule. I must commend Dr. Brennan on his laser sharp focus and attention to detail and I must also express my special gratitude to Zach Dutton and Peter Moriarty for their efforts in resolving some outstanding issues to close the transaction.”

Bokhari continued, “The Prismic acquisition represents strategic depth in the vision and mission of FSD Pharma and signals a paradigm shift in the overall outlook of the company. We are relying heavily on the expertise of Dr. Brennan, who is a seasoned pharmaceutical industry veteran with substantial experience from working at Glaxo Smith Kline and Johnson & Johnson to navigate us through the various stages of the FDA approval process for drug development, with the goal of eventually making synthetic cannabinoid prescription medications available for commercial use to help alleviate the pain and suffering of patients. We are confident, Peter Moriarty, another well-known pharmaceutical industry veteran, who was also one of the founders of Shire Pharmaceuticals, will make a meaningful contribution to the FSD Pharma story as the chairman of the BioPharmaceutical industry advisory board.”

InMed Pharmaceuticals Inc. (TSX:IN) (OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis technology for cannabinoid-based pharmaceuticals to treat severe diseases, today announced the appointment of Catherine Sazdanoff, JD, to its Board of Directors.

Ms. Sazdanoff joins InMed's Board with 35 years of experience in the healthcare industry. She held various global VP roles in business development and corporate development at Takeda Pharmaceuticals, which she joined in 2006. Prior to Takeda, Ms. Sazdanoff served in senior global legal and pharmaceutical business roles at Abbott Laboratories since 1984, including litigation, international commercial and transactional legal roles, marketing, and business development. At both companies, she completed numerous collaborations and transformational M&A transactions, including Abbott's acquisition of Knoll Laboratories (including the mega-blockbuster drug Humira®), and Takeda's acquisition of Millennium Pharmaceuticals and Nycomed S.A.

Ms. Sazdanoff is an independent director of the Board of Meridian Bioscience, Inc. (NASDAQ: VIVO). She is currently President and CEO of Sazdanoff Consulting LLC, where she acts as Business Advisor to Strata Oncology, Inc., a private precision oncology company, and works with other healthcare companies on strategy and corporate/business development. Ms. Sazdanoff has a BA in English from the University of Notre Dame, and a JD from Northwestern University School of Law.

"We are enthusiastic to welcome Catherine to our Board of Directors at an exciting time in the Company's evolution," commented Eric A. Adams, President and Chief Executive Officer. "Her diverse business development and legal experience, built from over 35 years in the pharmaceutical industry, will be important as we accelerate the development of our therapeutic pipeline and scale-up our innovative biosynthesis platform technology. Importantly, Catherine's rich experience in pharma deal making will be highly beneficial to InMed as our assets mature and we begin strategizing about potential transactions."
"InMed has unique opportunities to bring significant medical advances to important patient populations with its differentiated cannabinoid-based therapeutic pipeline and novel biosynthesis manufacturing technology," stated Ms. Sazdanoff. "I am delighted to join the team and look forward to working closely with the Company's management as InMed drives towards long-term value creation."

Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   


Subscribe to the new cannabis podcast series:


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Follow us on Social Media

Contact Investorideas.com
800-665-0411


  

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directories


Investorideas.com - The Acquisition Flurry In Cannabis and CBD Continue (OTC: $SIML) (TSX: $WEED.TO) (NYSE: $CGC) (CSE: $CRFT.C) (CSE: $IAN.C) (OTCQX: $ITHUF)

Investorideas.com - The Acquisition Flurry In Cannabis and CBD Continue (OTC: $SIML) (TSX: $WEED.TO) (NYSE: $CGC) (CSE: $CRFT.C) (CSE: $IAN.C) (OTCQX: $ITHUF)

Monday, 1 July 2019

Recent #CBD / #Cannabis Acquisitions (OTC: $SIML) (TSX: $WEED.TO) (NYSE: $CGC) (CSE: $CRFT.C) (CSE: $IAN.C) (OTCQX: $ITHUF)


Recent #CBD / #Cannabis Acquisitions (OTC: $SIML) (TSX:  $WEED.TO) (NYSE: $CGC) (CSE: $CRFT.C) (CSE: $IAN.C) (OTCQX: $ITHUF)

Point Roberts WA, Delta BC – July 1, 2019 - Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a multi-media snapshot reporting on recent acquisitions in the CBD cannabis space.

Viridian’s Deal Tracker recently noted, “Acquisitions of companies in the hemp sector accelerate worldwide as industrial and consumer hemp/CBD markets develop.”

Driving the acquisition flurry; the collective market for CBD sales is expected to exceed $20 billion in the United States by 2024, according to BDS Analytics and Arcview Market Research.

Aiming to capitalize on this, Simlatus Corporation (OTC PINK:SIML), a holding company focused on opportunities in the cannabis space just announced that the Company is cleaning up corporately to be better positioned for acquisitions in the future.


From the news - “During the past several months the Company has retired and returned to treasury $2.7M in Convertible Debt using its cash reserves to quarantine toxic conversions, stock dilution and preserve its equity.“
  
Continued: Richard Hylen, Chairman and CEO stated “Our shareholders and management team have been on an impressive run ever since the company expanded its footprint into the cannabis sector with our most recent acquisition of Proscere Bioscience. With this acquisition, the company gained access to a cold-water CBD extraction Technology that presents an exciting opportunity on revenue generation. With the acquisition, the company has gained access to a valuable asset capable of strengthening its revenue base, with a current $2.8M in its first purchase order, and commitments of $275M over the next 5 years. The company has already set sights on Canada, USA, and Europe as it embarks on an aggressive commercialization drive for the cold-water CBD extraction systems.”

Cannabis leader, Canopy Growth Corporation (TSX:WEED) (NYSE:CGC) is also completing an acquisition in extraction technology, announcing on June 26th that it has completed a transaction to acquire Saskatoon-based bio-product extractor KeyLeaf Life Sciences, related entities and intellectual property.  “Canopy Growth has been working closely with KeyLeaf – formerly known as POS Bio-Sciences – as a trusted partner building out extraction processes and technology for the past year as it refines its scale extraction model for Canadian and global markets. As previously disclosed, Canopy Growth assumed control of KeyLeaf for accounting purposes in November 2018. As such, KeyLeaf’s financial results were consolidated in the Company’s fiscal 2019 financial statements. Through the transaction, the Company is acquiring a large-scale Canadian extraction facility as well as an extraction-related facility in the United States to support the Company’s US CBD expansion.”

Continued: “With over 45 years of experience in the canola, nutraceutical, cosmetic and bio-product industries, KeyLeaf is a recognized leading authority with significant intellectual property relating to plant-based extraction and ingredients. The extensive experience of KeyLeaf’s chemists, engineers, and operators will remain within the organization to further refine the cannabinoid extraction process and will support Canopy Growth in the design, training, oversight, and implementation of additional extraction sites around the world.”

Continued: “KeyLeaf has been working closely with Canopy Growth over the past year to retrofit its Saskatchewan facility to advance technology development and commercialization, in order to process hemp and cannabis biomass, and to conduct pre- and post-extraction processes.  It is anticipated the facility, which is currently in the Health Canada licensing process, will be able to process up to 5,000 kg of input materials daily when operational.”

Continued: “Canopy Growth intends to leverage this facility, along with other owned and partner extraction options, to process its over 5,000 acres of Canadian CBD hemp production, over 160 acres of outdoor cannabis production, as well as any extraction materials outputted from its over 4 million square feet of greenhouse growing operations.  Then it’s off to Smiths Falls to produce the best possible, IP-protected products out there!”

Looking at other recent acquisition news in the sector, Pasha Brands Ltd. (CSE: CRFT) (OTC:CRFTF), Canada's largest craft cannabis brands organization, announced on June 24th the acquisition of the CBD Therapeutics brand – a leading pre-legalization manufacturer and purveyor of cannabidiol (CBD) product based in British Columbia.

Continued: “Since its inception, CBD Therapeutics has supplied solvent-less full spectrum and isolated CBD formulations to the pre-legalization market throughout Canada, and increased access to both products and education. Since ceasing sales on October 17, 2018, CBD Therapeutics has been preparing to enter the regulated framework. Pasha has acquired all of the brand's trademarks, names and intellectual property and will re-launch the brand in the Canadian regulated market in the very near future.” 

Continued: "Joining Pasha Brands is yet another step forward in our mission of making CBD products more accessible," said James Whitehead, CEO of CBD Therapeutics. "Working with a collective of smart, like minded individuals and brands will help open opportunities for CBD Therapeutics and aid our growth. It already has."

Finalizing a previously announced acquisition, iAnthus Capital Holdings, Inc. (CSE: IAN, OTCQX: ITHUF), which owns, operates and partners with best-in-class regulated cannabis operations across the United States, announced  on June 28th that its US subsidiary has closed the previously announced acquisition of CBD For Life, a top-ranked, national CBD brand in the US.

Continued: “CBD For Life has experienced accelerating revenue growth, from both existing customers and new account additions—representing approximately 50% quarter over quarter growth. CBD For Life's products are sold directly to consumers online at www.cbdforlife.us as well as in over 1,000 retail locations in 46 states, with a dedicated sales channel working with national retailers to on-board new locations weekly. CBD For Life's roster of national retailers include Urban Outfitters, Paper Source, Of a Kind, Olympia Sports, and Weis Markets, with others soon to be announced. Since announcing the Urban Outfitters relationship in mid-April 2019, the retailer has expanded the lineup of CBD For Life products it carries and the number of retail locations in which it offers them. CBD For Life's CBD-infused wellness, self-care, and beauty products have been featured in a wide range of cable, online, and print publications—including on NBC's Today Show and Telemundo47.”

Continued: “According to industry experts, U.S. retail sales of CBD consumer products are estimated to have been between $600 million and $2 billion in 2018. As a growing number of CBD brands and product types become increasingly available through diverse retail channels, the CBD market is projected to generate $16 billion in U.S. retail sales by 2025. Research has shown that nearly 7% of the U.S. population in January of 2019 reported using CBD as a supplement, and that number is expected to grow to at least 10% by 2025.”

“CBD sales have exploded in the past several months, but there’s still a long way to go when it comes to consumer, retailer, and manufacturer knowledge,” said Jessica Lukas, Vice President of Consumers Insights at BDS Analytics. “56 percent of adults 21+ do not know or are confused about the differences between THC and CBD.”

As the consumer matures, so will the industry and the hunt for acquisitions will continue to find the best in breed within the sector.

Read the full article/snapshot on Investorideas.com 

For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 
Follow us on Cannabis Social Media

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Disclosure: this news article SIML is a paid for service( two thousand ) on  Investorideas.com - third party . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com
800-665-0411


Get more Marijuana, hemp & cannabis stock investor ideas- news, articles, podcasts and stock directories




Trial Could Position Eco-Friendly Fertilizer for Organic Cannabis Market

Trial Could Position Eco-Friendly Fertilizer for Organic Cannabis Market